Hepatitis B virus (HBV) infection and its sequelae which include cirrhosis and hepatocellular carcinoma is a major public health problem throught the world.The WHO strategy for effective control of HBV infection is vaccination with the surface antigen of virus(HBsAg).The results obtained from a large number of studies demonstrated that the vaccine induces a protective antibody resonse (anti-HB...

PURPOSE To detect seroconversion of hepatitis B vaccine and antibody waning 3 years after vaccination in children immunized according to the World Health Organization schedule and its relationship to the mother's serostatus during pregnancy. METHODS A serological study was carried out in São José dos Campos. Blood samples from pregnant women were taken for hepatitis B marker serology. To eval...

OBJECTIVE To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire. METHODS Data were extracted from 2021 paired mother-infant records for the year 2000 birth cohort in New Hampshire's 25 delivery hospitals. Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vacci...

unresponsiveness to hepatitis b surface antigen (hbsag) has been shown to be associated with dysfunction of the presenting cells (apc) and defect in the specific b-lymphocyte and/or t-lymphocyte repertoires.   direct determination of the frequency of specific t-lymphocytes together with complementary analysis of the naive circulating immune cells could provide valuable information about the cel...

BACKGROUND Egypt is considered a region of the intermediate prevalence of hepatitis B virus (HBV) infection (4.5%). Seroprotection is assured when hepatitis B surface antibody (HBsAb) levels are ≥ 10 mIU/mL. Our study aimed to evaluate and compare the long-term immunogenicity and efficacy of the recombinant hepatitis B (HB) vaccine. METHODS A cross-sectional study was done for children aged f...

Hepatitis B is one of the alarming diseases globally. There are about 350 million chronic carriers in the world and it is estimated that 75-100 million of them will die of liver cirrhosis and/or hepatocellular carcinoma. Treatment is expensive and cure rates are not impressive. The advent of recombinant DNA technology resulted in the development of rDNA vaccine using yeast as an expression syst...

OBJECTIVES To compare two vaccination schedules in delivering hepatitis B vaccine to at-risk genitourinary medicine clinic attenders. SETTING Genitourinary medicine clinic of St Thomas' Hospital, London, UK. METHODS Two vaccination protocols were compared. Between January 1991 and December 1992, individuals had doses of recombinant hepatitis B vaccine at 0, 1 and 6 months (standard). From J...

Background: Hepatitis B virus (HBV) infection causes significant morbidity and mortality worldwide. Occupational exposure of health care workers and medical students increases their risk of acquiring HBV infection, and many authorities recommend vaccination. However, significant proportions of health care workers do not receive HBV immunization, and remain at increased risk to HBV infection. Ob...